Topical Lopinavir–Ritonavir Composition for HPV Cervical Dysplasia
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for HPV-related cervical dysplasia and cervical cancer are invasive, costly, and have high morbidity, particularly in low-resource settings, and existing HIV protease inhibitors like ritonavir have shown limited efficacy in clinical trials.
Innovation Solution
Topical application of a synergistic combination of lopinavir and ritonavir in a pharmaceutically acceptable vehicle, such as a vaginal suppository or gel, to treat and prevent HPV-related cervical dysplasia and cancer, leveraging their unexpected synergistic effects to inhibit HPV progression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If invasive surgical treatments are used for HPV-related cervical dysplasia and cancer, then treatment effectiveness is improved, but patient morbidity and treatment cost increase significantly
Solution Approach 1:
The patent replaces mechanical surgical intervention with a chemical/pharmacological system. Topical protease inhibitors (lovastatin and ritonavir) are applied to chemically inhibit HPV protease activity, thereby preventing viral replication and lesion progression without mechanical tissue removal or invasion, thus maintaining treatment effectiveness while reducing patient morbidity
Solution Approach 2:
The patent introduces protease inhibitors as intermediary substances that mediate between the host cells and HPV virus. These compounds specifically target and inhibit the HPV protease enzyme, blocking viral maturation and assembly without directly damaging host tissues, thereby providing effective treatment with minimal side effects
2Ease of operation
If existing HIV protease inhibitors like ritonavir are used alone, then treatment simplicity is maintained, but therapeutic efficacy is insufficient
Solution Approach 1:
The patent combines two protease inhibitors (lovastatin and ritonavir) into a single topical formulation. This combination leverages the complementary mechanisms of action of both compounds, where lovastatin inhibits HCV protease and ritonavir inhibits HPV protease, achieving enhanced therapeutic efficacy while maintaining ease of application as a single topical treatment
Solution Approach 2:
The patent creates a composite pharmaceutical formulation containing both lovastatin and ritonavir in specific ratios (e.g., 1:1 or 2:1). This composite material provides synergistic antiviral activity against both HCV and HPV, overcoming the limitations of single-agent therapy while preserving the simplicity of topical administration
Data Source
Figure 1(A)~1(C)
Figure 1(D)~2
Figure 3A~4C
AI summary
Disclosed herein are compositions comprising lopinavir alone or in combination with ritonavir for use as a medicament in the treatment of cancer or benign proliferative disorders (warts) or in the prevention of the development of cancer. Pharmaceutical compositions formulated for topical application comprising a therapeutically effective amount of lopinavir or a therapeutically effective amount lopinavir and ritonavir in a pharmaceutically acceptable vehicle are also provided. Also disclosed are methods of treating a patient having an HPV related dysplasia of the cervix comprising administering to said patient a therapeutically effective dose of the disclosed pharmaceutical compositions.